FDA panel rejects Allergan's Tazoral

Article

National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.